Louvain-la-Neuve, Belgium, 3 February 2019 – IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions, is hosting its 8th annual Proteus® User Meeting from February 1 to February 3, in Miami, Florida. As the world’s leading vendor of proton therapy systems, with more than 29 sites in operation and another 25 under construction, IBA is continuously gathering input from its proton therapy users.

The users’ community is expanding every year. This year IBA welcomes more than 165 participants, representing 40 sites from 17 countries, making IBA’s proton therapy community the largest and most experienced in the industry.

This year’s User Meeting is hosted by the Miami Cancer Institute. The 395,000-square-foot Cancer Institute opened in January 2017 and is known for its unmatched dedication to multidisciplinary patient care, cutting edge technology and innovative cancer treatments.
The three-day User Meeting provides Proteus Users a platform for open dialogue, technical and clinical discussions, collaboration, and real-time feedback. Users discuss opportunities for innovation and new indications as well as clinical studies and treatment protocols. These shared experiences and combined expertise aid the advancement and adoption of proton therapy. Consequentially, the outcome of the meeting has many advantages that benefit IBA’s users and IBA as a whole. For instance, users are able to bring their experience to the User Meeting and leave with the new ideas for their centers. It also allows for IBA to acquire knowledge and feedback first-hand to continue championing advancements in proton therapy.

Olivier Legrain, Chief Executive Officer, IBA: “The theme of this year’s User Meeting is ‘Capturing New Opportunities in Proton Therapy.’ At IBA, we encourage creativity and applaud individuals for their contributions. We also believe in the power of teamwork and using a concerted approach to refine good ideas into transformative solutions. That is why we chose this theme that embodies our belief in the proton therapy community; to share and leverage our efforts together, and to challenge current practices. We can expand beyond the current boundaries of clinical acceptance, clinical operation, and clinical innovation, and ultimately, lead the way for the proper adoption of this powerful technology.”

Dr Minesh Mehta, Deputy Director and Chief of Radiation Oncology,Miami Cancer Institute: “We are very proud that IBA has chosen to hold the 2019 Users’ Meeting at Miami Cancer Institute - Baptist Health. We are excited to welcome such a large group of practitioners. Year after year, this meeting has demonstrated continued value to the proton community and offers a fantastic opportunity for proton therapy experts to share their knowledge and expertise. Miami Cancer Institute offers the world’s most comprehensive and advanced radiation oncology program under a single roof. We are the only cancer center to offer all of the major radiation therapies, including proton therapy in one location, which enables us to choose the right treatment for each patient and optimize the use of proton therapy in combination with other technologies.”


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Rad Oncology Homepage